Last reviewed · How we verify
monoclonal antibody 3H1 Alu Gel
monoclonal antibody 3H1 Alu Gel is a Biologic drug developed by Alliance for Clinical Trials in Oncology. It is currently in Phase 2 development. Also known as: CeaVac.
At a glance
| Generic name | monoclonal antibody 3H1 Alu Gel |
|---|---|
| Also known as | CeaVac |
| Sponsor | Alliance for Clinical Trials in Oncology |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- monoclonal antibody 3H1 Alu Gel CI brief — competitive landscape report
- monoclonal antibody 3H1 Alu Gel updates RSS · CI watch RSS
- Alliance for Clinical Trials in Oncology portfolio CI
Frequently asked questions about monoclonal antibody 3H1 Alu Gel
What is monoclonal antibody 3H1 Alu Gel?
monoclonal antibody 3H1 Alu Gel is a Biologic drug developed by Alliance for Clinical Trials in Oncology.
Who makes monoclonal antibody 3H1 Alu Gel?
monoclonal antibody 3H1 Alu Gel is developed by Alliance for Clinical Trials in Oncology (see full Alliance for Clinical Trials in Oncology pipeline at /company/alliance-for-clinical-trials-in-oncology).
Is monoclonal antibody 3H1 Alu Gel also known as anything else?
monoclonal antibody 3H1 Alu Gel is also known as CeaVac.
What development phase is monoclonal antibody 3H1 Alu Gel in?
monoclonal antibody 3H1 Alu Gel is in Phase 2.
Related
- Manufacturer: Alliance for Clinical Trials in Oncology — full pipeline
- Also known as: CeaVac
- Compare: monoclonal antibody 3H1 Alu Gel vs similar drugs
- Pricing: monoclonal antibody 3H1 Alu Gel cost, discount & access